Merck Company Leadership
MRK Stock | USD 131.95 0.20 0.15% |
About 90 percent of Merck's insiders are activelly selling. The analysis of insiders' sentiment of trading Merck Company stock suggests that many insiders are panicking at this time. Merck employs about 70 K people. The company is managed by 61 executives with a total tenure of roughly 445 years, averaging almost 7.0 years of service per executive, having 1147.54 employees per reported executive.
Kenneth Frazier Chairman Chairman of the Board, President, Chief Executive Officer |
Michael Rosenblatt President Executive Vice President Chief Medical Officer |
Merck's Insider Buying Vs Selling
10
Selling | Buying |
Latest Trades
2024-02-13 | Joseph Romanelli | Disposed 1000 @ 124.89 | View | ||
2024-02-02 | Steven Mizell | Disposed 50694 @ 126.65 | View | ||
2023-12-28 | Jared Moskowitz | Acquired @ 108.77 | |||
2023-11-09 | Johannes Jacobus Oosthuizen | Disposed 2081 @ 102.38 | View | ||
2023-11-08 | Richard R Deluca | Disposed 43823 @ 105.03 | View | ||
2023-10-24 | Greg Stanton | Disposed @ 103.02 | |||
2023-10-16 | Tommy Tuberville | Disposed @ 104.14 | |||
2023-09-26 | Greg Stanton | Acquired @ 105.39 | |||
2023-09-21 | Pete Ricketts | Disposed @ 106.73 | |||
2023-09-13 | Michael C. Burgess | Disposed @ 107.81 | |||
2023-09-11 | C. Scott Franklin | Disposed @ 108.59 | |||
2023-09-08 | Lois Frankel | Disposed @ 109.05 | |||
2023-09-06 | Lois Frankel | Disposed @ 106.51 | |||
2023-08-14 | Steven Mizell | Disposed 4250 @ 109.01 | View | ||
2023-08-03 | Steven Mizell | Disposed 4500 @ 105.49 | View | ||
2023-08-02 | Lois Frankel | Disposed @ 105.7 | |||
2023-07-14 | Daniel S. Goldman | Disposed @ 107.34 | |||
2023-07-12 | Daniel S. Goldman | Disposed @ 107.51 | |||
2023-06-28 | Lois Frankel | Disposed @ 112.45 | |||
2023-05-25 | Zoe Lofgren | Disposed @ 112.3 |
Monitoring Merck's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Merck's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Merck Company. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Merck's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Merck |
Merck's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Merck's future performance. Based on our forecasts, it is anticipated that Merck will maintain a workforce of about 70000 employees by April 2024.Merck's latest congressional trading
Congressional trading in companies like Merck Company, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Merck by those in governmental positions are based on the same information available to the general public.
2023-12-28 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2023-10-24 | Representative Greg Stanton | Disposed Under $15K | Verify | ||
2023-10-16 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
2023-09-21 | Senator John P Ricketts | Acquired $50K to $100K | Verify | ||
2023-09-11 | Representative C. Scott Franklin | Disposed $15K to $50K | Verify | ||
2022-09-15 | Representative Earl Blumenauer | Disposed $15K to $50K | Verify | ||
2022-03-30 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2021-09-16 | Representative Katherine M. Clark | Disposed Under $15K | Verify | ||
2021-07-28 | Representative Carol Devine Miller | Disposed $15K to $50K | Verify | ||
2021-07-19 | Representative John Curtis | Disposed Under $15K | Verify | ||
2021-03-05 | Representative Michael T. McCaul | Acquired $15K to $50K | Verify | ||
2021-01-13 | Representative Peter Meijer | Acquired Under $15K | Verify | ||
2020-04-14 | Senator David A Perdue , Jr | Acquired $50K to $100K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired $15K to $50K | Verify | ||
2019-07-12 | Representative Bryan George Steil | Disposed Under $15K | Verify | ||
2018-06-04 | Senator Susan M. Collins | Acquired Under $15K | Verify | ||
2018-01-04 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2018-01-04 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2017-11-29 | Representative Richard W. Allen | Disposed Under $15K | Verify | ||
2017-11-27 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify |
Merck Management Team Effectiveness
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Capital Employed is expected to slide to 0.04. The value of Return On Assets is estimated to slide to 0. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.Common Stock Shares Outstanding is expected to rise to about 2.7 B this year. Net Income Applicable To Common Shares is expected to rise to about 17.5 B this year
Merck Workforce Comparison
Merck Company is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 2.97 Million. Merck holds roughly 70,000 in number of employees claiming about 2.36% of equities under Health Care industry.
Merck Profit Margins
The company has Net Profit Margin of 0.01 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.74 | 0.7331 |
|
| |||||
Net Profit Margin | 0.0058 | 0.0061 |
|
| |||||
Operating Profit Margin | 0.0473 | 0.0498 |
|
| |||||
Pretax Profit Margin | 0.03 | 0.0316 |
|
| |||||
Return On Assets | 0.0033 | 0.0034 |
|
| |||||
Return On Equity | 0.0092 | 0.0097 |
|
|
Merck Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Merck insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.0476 | 22 | 21 | 594,420 | 770,979 |
2023-12-01 | 1.2 | 6 | 5 | 13,638 | 47,270 |
2023-09-01 | 0.8333 | 5 | 6 | 38,000 | 63,729 |
2023-06-01 | 1.18 | 59 | 50 | 1,178,546 | 1,031,938 |
2023-03-01 | 1.1765 | 20 | 17 | 262,301 | 433,760 |
2022-12-01 | 0.4588 | 39 | 85 | 2,658,958 | 8,578,449 |
2022-09-01 | 2.75 | 11 | 4 | 159,041 | 13,087 |
2022-06-01 | 1.7292 | 83 | 48 | 1,509,214 | 103,395 |
2022-03-01 | 5.25 | 21 | 4 | 244,707 | 1,679 |
2021-12-01 | 0.7308 | 19 | 26 | 1,045,649 | 2,081,014 |
2021-09-01 | 4.0 | 4 | 1 | 1,165 | 0.00 |
2021-06-01 | 1.0625 | 51 | 48 | 1,472,019 | 196,781 |
2021-03-01 | 3.6 | 18 | 5 | 361,717 | 4,154 |
2020-12-01 | 0.7 | 7 | 10 | 261,384 | 796,099 |
2020-09-01 | 0.7143 | 5 | 7 | 37,936 | 102,528 |
2020-06-01 | 1.2 | 42 | 35 | 1,319,129 | 150,911 |
2020-03-01 | 4.0 | 20 | 5 | 324,059 | 184,621 |
2019-12-01 | 0.9 | 9 | 10 | 22,061 | 41,948 |
2019-09-01 | 1.75 | 7 | 4 | 39,722 | 76,252 |
2019-06-01 | 1.1892 | 44 | 37 | 1,445,367 | 779,888 |
2019-03-01 | 0.9211 | 35 | 38 | 1,257,748 | 2,091,430 |
2018-12-01 | 1.2 | 18 | 15 | 1,040,955 | 1,783,786 |
2018-09-01 | 0.9167 | 11 | 12 | 639,652 | 1,305,407 |
2018-06-01 | 2.0 | 42 | 21 | 1,432,383 | 458,982 |
2018-03-01 | 1.0625 | 17 | 16 | 445,370 | 371,642 |
2017-12-01 | 2.3333 | 7 | 3 | 20,632 | 10,750 |
2017-06-01 | 1.7143 | 36 | 21 | 1,553,474 | 361,844 |
2017-03-01 | 1.4211 | 27 | 19 | 455,261 | 315,667 |
2016-12-01 | 0.8824 | 15 | 17 | 293,276 | 582,646 |
2016-09-01 | 0.5217 | 12 | 23 | 578,193 | 1,197,540 |
2016-06-01 | 1.5185 | 41 | 27 | 2,651,735 | 797,485 |
2016-03-01 | 16.0 | 16 | 1 | 232,128 | 5,500 |
2015-12-01 | 1.0 | 9 | 9 | 68,677 | 140,958 |
2015-09-01 | 1.0 | 14 | 14 | 64,343 | 100,125 |
2015-06-01 | 1.2821 | 50 | 39 | 2,716,324 | 988,397 |
2015-03-01 | 1.5625 | 25 | 16 | 405,153 | 464,088 |
2014-12-01 | 0.75 | 15 | 20 | 110,014 | 207,166 |
2014-09-01 | 0.7143 | 15 | 21 | 248,992 | 697,495 |
2014-06-01 | 1.25 | 55 | 44 | 2,250,265 | 791,303 |
2014-03-01 | 1.1818 | 26 | 22 | 326,427 | 386,720 |
2013-12-01 | 1.2 | 6 | 5 | 45,607 | 65,674 |
2013-09-01 | 1.3333 | 12 | 9 | 53,027 | 101,276 |
2013-06-01 | 1.2727 | 56 | 44 | 2,771,893 | 1,205,980 |
2013-03-01 | 3.6 | 18 | 5 | 147,652 | 45,194 |
2012-12-01 | 0.9333 | 14 | 15 | 555,297 | 1,091,760 |
2012-09-01 | 0.8 | 12 | 15 | 268,289 | 168,349 |
2012-06-01 | 2.3182 | 51 | 22 | 2,545,153 | 279,977 |
2012-03-01 | 0.7778 | 21 | 27 | 193,448 | 169,666 |
2011-12-01 | 2.1667 | 13 | 6 | 314,573 | 73,033 |
2011-06-01 | 1.4865 | 55 | 37 | 2,376,944 | 231,055 |
2011-03-01 | 1.2963 | 35 | 27 | 530,831 | 246,535 |
2010-12-01 | 1.625 | 13 | 8 | 53,246 | 85,768 |
2010-09-01 | 5.6 | 28 | 5 | 126,239 | 56,877 |
2010-06-01 | 28.5 | 57 | 2 | 2,423,858 | 63,533 |
2010-03-01 | 1.0 | 41 | 41 | 507,663 | 475,014 |
2009-12-01 | 0.8771 | 264 | 301 | 8,555,363 | 23,366,896 |
2009-09-01 | 4.0 | 8 | 2 | 23,925 | 13,635 |
2009-06-01 | 2.7273 | 60 | 22 | 2,731,491 | 652,744 |
2009-03-01 | 3.2 | 16 | 5 | 605,451 | 71,518 |
2008-06-01 | 2.4118 | 41 | 17 | 2,734,939 | 641,756 |
2008-03-01 | 0.5 | 2 | 4 | 22,674 | 58,708 |
2007-12-01 | 4.6667 | 14 | 3 | 21,656 | 7,481 |
2007-09-01 | 0.5 | 1 | 2 | 30,000 | 43,905 |
2007-06-01 | 0.6078 | 31 | 51 | 4,094,044 | 2,234,949 |
2007-03-01 | 1.0 | 7 | 7 | 178,626 | 115,256 |
2006-12-01 | 0.8846 | 23 | 26 | 522,366 | 759,412 |
2006-09-01 | 0.5 | 2 | 4 | 125,000 | 236,088 |
2006-06-01 | 44.0 | 44 | 1 | 2,985,832 | 46,350 |
2006-03-01 | 7.5 | 15 | 2 | 106,947 | 17,660 |
2005-12-01 | 1.3333 | 12 | 9 | 48,070 | 60,268 |
2005-09-01 | 1.2 | 6 | 5 | 106,290 | 206,165 |
2005-06-01 | 7.75 | 31 | 4 | 3,306,390 | 208,091 |
2005-03-01 | 4.5 | 9 | 2 | 14,727 | 18,875 |
2004-12-01 | 1.0 | 7 | 7 | 32,839 | 41,795 |
2004-03-01 | 5.9167 | 71 | 12 | 6,686,944 | 385,239 |
2003-12-01 | 2.9167 | 70 | 24 | 1,319,854 | 395,457 |
2003-09-01 | 14.6667 | 44 | 3 | 231,444 | 153,435 |
2003-06-01 | 4.0 | 12 | 3 | 25,912 | 58,292 |
2003-03-01 | 0.6667 | 2 | 3 | 246,100 | 127,090 |
Merck Notable Stakeholders
A Merck stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Merck often face trade-offs trying to please all of them. Merck's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Merck's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kenneth Frazier | Chairman of the Board, President, Chief Executive Officer | Profile | |
Robert JD | President Chairman | Profile | |
Michael Rosenblatt | Executive Vice President Chief Medical Officer | Profile | |
Caroline Litchfield | Chief Financial Officer, Executive Vice President | Profile | |
Mirian GraddickWeir | Executive Vice President - Human Resources | Profile | |
Julie Gerberding | Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | Profile | |
Franklin Clyburn | President, Human Health, Head of Human Health Commercial and Marketing | Profile | |
Robert Davis | Executive Vice President, Global Services, Chief Financial Officer | Profile | |
Steven Mizell | Executive Vice President, Chief Human Resources Officer, Human Resources | Profile | |
Jim Scholefield | Executive Vice President, Chief Information and Digital Officer | Profile | |
Sanat Chattopadhyay | Executive Vice President and President - Merck Manufacturing Division | Profile | |
Adam Schechter | President of Global Human Health and Executive VP | Profile | |
Cristal Downing | Executive Vice President, Chief Communications, Public Affairs Officer | Profile | |
Jennifer Zachary | Executive Vice President, General Counsel, Corporate Secretary | Profile | |
Michael Holston | Executive Vice President Chief Ethics and Compliance Officer | Profile | |
Adele Ambrose | Senior Vice President Chief Communications Officer | Profile | |
Willie Deese | Executive Vice President and Presidentident - Merck Manufacturing Division | Profile | |
Michael Nally | Executive Vice President, Chief Marketing Officer | Profile | |
Roger Perlmutter | Executive Vice President and Presidentident - Merck Research Laboratories | Profile | |
Ashley Watson | Senior Vice President Chief Ethics and Compliance Officer | Profile | |
Richard DeLuca | Executive Vice President and Presidentident - Merck Animal Health | Profile | |
Frank Clyburn | Executive Vice President, Chief Commercial Officer | Profile | |
Clark Golestani | CIO and Executive VP | Profile | |
Rita Karachun | Principal Accounting Officer, Sr. VP of Fin. and Global Controller | Profile | |
Rochelle Lazarus | Independent Director | Profile | |
Paul Rothman | Independent Director | Profile | |
Mary Coe | Independent Director | Profile | |
Patricia Russo | Independent Director | Profile | |
Robert Kidder | Independent Director | Profile | |
Thomas Cech | Independent Director | Profile | |
William Harrison | Lead Independent Director | Profile | |
Thomas Glocer | Lead Independent Director | Profile | |
Craig Thompson | Independent Director | Profile | |
Christine Seidman | Independent Director | Profile | |
Wendell Weeks | Independent Director | Profile | |
Kathy Warden | Independent Director | Profile | |
Peter Wendell | Independent Director | Profile | |
John Noseworthy | Independent Director | Profile | |
Leslie Brun | Lead Independent Director | Profile | |
Inge Thulin | Independent Director | Profile | |
Pamela Craig | Independent Director | Profile | |
Carlos Represas | Independent Director | Profile | |
Scot Ebbinghaus | VP Development | Profile | |
Gregory Lubiniecki | VP Development | Profile | |
Michael Fleming | Senior Vice President Chief Ethics and Compliance Officer | Profile | |
Jannie Oosthuizen | Lead - Human Health U.S. | Profile | |
Jennifer Mauer | VP Communications | Profile | |
Michael Klobuchar | Executive Vice President Chief Strategy Officer | Profile | |
David Williams | Executive Vice President Chief Information Chief Information and Digital Officer | Profile | |
Lisa LeCointeCephas | Senior Vice President Chief Ethics and Compliance Officer | Profile | |
Deepak Khanna | Lead - Human Health International | Profile | |
Gideon Blumenthal | Vice Affairs | Profile | |
Risa LavizzoMourey | Independent Director | Profile | |
Arpa Garay | Lead - Human Health Global Marketing | Profile | |
Dalton III | Principal Finance | Profile | |
Joseph Romanelli | IR Contact Officer | Profile | |
Dean Li | Executive Vice President and Presidentident, Merck Research Laboratories | Profile | |
Chirfi Guindo | Senior Health | Profile | |
Joerg Koglin | Vice Development | Profile | |
Stephen Mayo | Independent Director | Profile | |
Peter Dannenbaum | Vice Relations | Profile |
About Merck Management Performance
The success or failure of an entity such as Merck Company often depends on how effective the management is. Merck management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Merck management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Merck management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.04 | 0.04 | |
Return On Assets | 0 | 0 | |
Return On Equity | 0.01 | 0.01 |
The data published in Merck's official financial statements usually reflect Merck's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Merck Company. For example, before you start analyzing numbers published by Merck accountants, it's critical to develop an understanding of what Merck's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Merck's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Merck's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Merck's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merck Company. Please utilize our Beneish M Score to check the likelihood of Merck's management manipulating its earnings.
Merck Workforce Analysis
Traditionally, organizations such as Merck use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Merck within its industry.Merck Manpower Efficiency
Return on Merck Manpower
Revenue Per Employee | 855.3K | |
Revenue Per Executive | 981.5M | |
Net Income Per Employee | 5.2K | |
Net Income Per Executive | 6M | |
Working Capital Per Employee | 92.5K | |
Working Capital Per Executive | 106.1M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.